Logo: to the web site of Uppsala University

uu.sePublications from Uppsala University
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
Matrix-M adjuvant triggers inflammasome activation and enables antigen cross-presentation through induction of lysosomal membrane permeabilization
Novavax AB, Uppsala, Sweden..
Novavax AB, Uppsala, Sweden..
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Faculty of Medicine, Department of Medical Biochemistry and Microbiology, Infection and Immunity.ORCID iD: 0000-0002-8945-2665
Novavax AB, Uppsala, Sweden..
Show others and affiliations
2025 (English)In: npj Vaccines, E-ISSN 2059-0105, Vol. 10, no 1, article id 184Article in journal (Refereed) Published
Abstract [en]

Matrix-M® adjuvant, containing saponins, delivers a potent adjuvant effect and good safety profile. Given that Matrix-M is composed of Matrix-A and Matrix-C particles, comprising different saponin fractions, understanding their distinct roles can provide deeper insight into the mechanism of action of Matrix-M and guide future applications. Here, we demonstrate that the antigen and Matrix-M, Matrix-A, or Matrix-C colocalize in lysosomes following uptake by bone marrow–derived dendritic cells. Matrix-M, Matrix-A, and Matrix-C induce lysosomal membrane permeabilization (LMP), but Matrix-C shows the highest LMP potential. LMP is required for interleukin (IL)-1β and IL-18 secretion in vitro. In vivo, a robust adjuvant effect of Matrix-M, Matrix-A, and Matrix-C is observed, both in the presence and absence of the NLRP3 inflammasome. LMP induced by Matrix-M, as well as Matrix-A and Matrix-C, also enables antigen cross-presentation. Thus, Matrix-induced LMP explains the capability of Matrix-M–adjuvanted protein vaccines to induce CD8+ T-cell responses.

Place, publisher, year, edition, pages
Springer Nature, 2025. Vol. 10, no 1, article id 184
National Category
Immunology in the Medical Area
Identifiers
URN: urn:nbn:se:uu:diva-565595DOI: 10.1038/s41541-025-01243-5ISI: 001544699700002PubMedID: 40764493Scopus ID: 2-s2.0-105012604563OAI: oai:DiVA.org:uu-565595DiVA, id: diva2:1993941
Funder
Swedish Foundation for Strategic ResearchAvailable from: 2025-09-01 Created: 2025-09-01 Last updated: 2025-09-01Bibliographically approved

Open Access in DiVA

fulltext(4597 kB)379 downloads
File information
File name FULLTEXT01.pdfFile size 4597 kBChecksum SHA-512
de7289560c9334cbef7e441e5cc7bdf00c79018e0c7a3a99068968e755324d6b433cbc3cc6576e024ba4f3e4b4f72e63d804d6a714b081d655476f9fa67d11b3
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMedScopus

Authority records

Eriksson, JensSellin, Mikael E.

Search in DiVA

By author/editor
Eriksson, JensSellin, Mikael E.
By organisation
Infection and ImmunityScience for Life Laboratory, SciLifeLab
In the same journal
npj Vaccines
Immunology in the Medical Area

Search outside of DiVA

GoogleGoogle Scholar
Total: 380 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

doi
pubmed
urn-nbn

Altmetric score

doi
pubmed
urn-nbn
Total: 442 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf